The most recent trading session ended with Boston Scientific (BSX) standing at $76.31, reflecting a +0.16% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 0.25%. On the other hand, the Dow registered a gain of 0.15%, and the technology-centric Nasdaq increased by 0.03%. Coming into today, shares of the medical device manufacturer had gained 1.1% in the past month. In that same time, the Medical sector gained 0.11%, while the S&P 500 gained 3.34%. The upcoming ear ...

Key Takeaways Boston Scientific has purchased Silk Road Medical, which makes products to help prevent strokes in patients with carotid artery disease. The company is paying $1.26 billion for Silk Road, or $27.50 per share, a 27% premium to Monday's closing price. Boston Scientific said the acquisition will not be accretive to its adjusted earnings per share until 2026. Shares of Silk Road Medical (SILK) soared in intraday trading Tuesday after Boston Scientific (BSX) announced it was buying the medical devi ...

Loading... Loading... Tuesday, Boston Scientific Corporation BSX agreed to acquire Silk Road Medical Inc SILK for $27.50 in cash per share, representing an equity value of approximately $1.26 billion. The per-share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical’s common stock over the past 60 days. Related: Heart Devices Focused Silk Road Medical Stock Gets an Upgrade – Analyst Says New CEO’s Initiatives Sets Stage For ‘Back On Track’ Silk Road Me ...

Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. ("Silk Road") (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation ("Boston Scientific") (NYSE:BSX), a global medical technology leader, for $27.50 in cash per share, representing an equity value of approxim ...

Acquisition adds innovative technology for stroke prevention to vascular portfolio MARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR) ...

In the latest market close, Boston Scientific (BSX) reached $77.41, with a +0.34% movement compared to the previous day. The stock lagged the S&P 500's daily gain of 0.85%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, added 1.53%. Shares of the medical device manufacturer have appreciated by 4.98% over the course of the past month, outperforming the Medical sector's gain of 2.46% and the S&P 500's gain of 3.11%. Market participants will be closely following the financial results of Bos ...

CHICAGO, June 11, 2024 (GLOBE NEWSWIRE) -- VelocityEHS®, the global leader in enterprise EHS & ESG software solutions, celebrates Boston Scientific for being named the 2024 Verdantix EHS Innovation Excellence EMEA award winner in the category Operational Risk Management. Boston Scientific, a world leader in innovative medical device solutions, received this honor for its manufacturing facility in Cork, Ireland, where it streamlined the permit and contractor management program using the VelocityEHS Control o ...

文章核心观点 - 公司正在积极拓展海外市场,特别是新兴市场,带动收入增长 [4][5][6] - 公司通过一系列收购交易,进一步丰富了产品组合,提升了市场地位 [7][8] - 公司财务状况稳健,偿债能力较强 [9][10] - 但公司面临宏观经济环境恶化和汇率波动等不利因素 [11][12] 根据相关目录分别进行总结 公司业务发展 - 公司在新兴市场如欧洲、亚太地区实现了强劲增长,尤其在心电生理学、内窥镜、泌尿外科等领域表现出色 [4][5][6] - 公司通过收购B. Braun的内腔负压治疗业务、Axonics的创新医疗设备、Relievant Medsystems的骨内神经消融系统等,进一步丰富了产品线,提升了市场地位 [7][8] 财务状况 - 公司现金和现金等价物达23.3亿美元,短期债务10.9亿美元,总债务10.62亿美元,总债务资本比34.1% [9][10] - 利息保障倍数达9%,为近4个季度最高,显示公司偿债能力较强 [10] 行业环境 - 公司面临地缘政治压力、供应链中断等宏观经济挑战,导致成本上升,毛利率下降 [11] - 汇率波动也对公司收入造成一定负面影响 [12]

It has been about a month since the last earnings report for Boston Scientific (BSX) . Shares have added about 1.5% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Boston Scientific Q1 Earnings Bea ...

Boston Scientific (BSX) is gaining traction in the emerging markets. New regulatory approvals bode well for the company’s growth. The stock carries a Zacks Rank #2 (Buy) currently. Boston Scientific continues to expand operations across different geographies outside the United States. In 2023, 41% of the company’s consolidated revenues came from international regions. Within its international regions, the company is putting additional efforts to expand its foothold in the emerging markets (defined as all co ...